Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.89 USD | +2.03% | +1.71% | -18.67% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.67% | 80.53B | |
+30.63% | 695B | |
+26.51% | 568B | |
-4.63% | 361B | |
+19.57% | 330B | |
+3.79% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+7.90% | 168B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89